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KeyPoints:

1) The main public health insurance scheme in Ireland (GMS) provides primary care to 
approximately 40% of the population, generally on a means tested basis, but also on the basis 
of older age.  
2) Until 2010 prescription medicines were free at the point of access on this scheme. In 2010 
each prescription item was made subject to a €0.50 copayment. This was increased to €1.50 
per item in 2013. 
3) We found that both copayments had a larger impact on adherence to less-essential medicines 
than essential medicines, consistent with the prior literature. 
4) Notably, in comparison to other essential medicines, relatively larger reductions in adherence 
to anti-depressant medicines were observed after each copayment intervention. 
5) Further analyses of our results on anti-depressant medicines, in addition to analyses for 
clinical outcomes and variability according to socio-economic status within the GMS 
population, would increase our understanding of the wider impact of this copayment policy.  

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Abstract

Purpose 
We assessed the impact of the introduction of a €0.50 prescription copayment, and its 
increase to €1.50, on adherence to essential and less-essential medicines in a publicly insured 
population in Ireland. 
Methods 
We used a pre-post longitudinal repeated measures design. We included new users of blood 
pressure lowering, lipid lowering and oral diabetic agents, thyroid hormone, anti-depressants, 
non-steroidal anti-inflammatory drugs (NSAIDs), Proton Pump Inhibitors/H2 antagonists 
(PPIs/H2) and anxiolytics/hypnotics. The outcome was change in adherence, measured using 
proportion of days covered. We used segmented regression with generalised estimating 
equations to allow for repeated measurements.  
Results 
Sample sizes ranged from 7,145 (thyroid hormone users) to 136,111(NSAID users). The 
€0.50 copayment was associated with reductions in adherence ranging from -2.1%[95% CI, -
2.8 to -1.5] (thyroid hormone) to -8.3%[95% CI, -8.7 to -7.9] (anti-depressants) for essential 
medicines and reductions of -2%[95% CI, -2.3 to -1.7] (anxiolytics/hypnotics) to -9.5%[95% 
CI, -9.8 to -9.1] (PPIs/H2) for less-essential medicines. The €1.50 copayment generally 
resulted in smaller reductions in adherence to essential medicines. Antidepressant 
medications were the exception with a decrease of -10.0% [95% CI, -10.4 to -9.6] after the 
copayment increase. Larger decreases in adherence were seen for less-essential medicines; 
the largest was for PPIs/H2 at -13.5% [95% CI, -13.9 to -13.2] after the €1.50 copayment.  
Conclusion 
4

Both copayments had a greater impact on adherence to less-essential medicines than essential 
medicines. The major exception was for anti-depressant medicines.  Further research is 
required to explore heterogeneity across different socio-economic strata and to elicit the 
impact on clinical outcomes.  
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Introduction1
2
The dramatic collapse of the Irish economy in 2008 coincided with an all time high in 3
pharmaceutical expenditure on the country’s main public health insurance programme, called 4
the General Medical Services (GMS) scheme. Spending for prescription medicines and 5
devices on this scheme increased from €339 million in 2000 to approximately €1.2 billion in 6
2010.1 Compared to Organisation for Economic Co-operation and Development (OECD) 7
countries in 2009, the level of public spending for pharmaceuticals in Ireland was exceeded 8
only by Greece, Canada and the U.S.2 Given the economic landscape, and amid pressures 9
from the EU-IMF-ECB troika to reduce public spending, a window of opportunity existed to 10
implement cost containment strategies with the goal of achieving better value for money in 11
pharmaceuticals.3  12
One such strategy was the introduction of a copayment policy. In October 2010, a €0.50 13
copayment per prescription item (capped at €10 per household per month) was introduced on 14
the GMS scheme. This was later increased to €1.50 in January 2013 (capped at €19.50). The 15
rationale behind copayments for prescription medicines is twofold. First is their role in moral 16
hazard, an economic principle describing the inefficient use of prescription medicines by 17
patients when supplied at zero cost by a third party payer e.g. the government.4 Second is 18
their role in saving costs or generating revenue.4 Along with these intended effects, 19
copayment policies also have some negative consequences for medication taking behaviours, 20
impacting on patient outcomes.  21
A study by Tambyln et al. is one of the most cited papers in the area of copayments for 22
prescription medicines.5 The authors found that the introduction of a 25% coinsurance fee for 23
prescription medicines in older individuals and those who received welfare benefits in 24
Quebec was associated with decreased adherence to essential medicines typically used in 25
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
chronic disease. Linkable hospital and pharmacy databases allowed the authors to associate 26
these decreases in adherence with increased hospitalisations and mortality.  This study is 27
significantly relevant to the Irish setting given the socio-economic and demographic 28
similarities between the GMS population and the population studied by Tamblyn et al. 29
Qualification for the GMS is on the basis of means-testing,  so the majority who qualify have 30
low-incomes, and due to higher income thresholds, most people aged over 70 years also are 31
also covered.6 Other frequently cited papers that demonstrate a positive relationship between 32
cost-sharing for prescription medicines and: hospitalizations and death7; nursing home 33
admissions8; or use of mental health services9 provide high quality evidence, but are less 34
applicable to the Irish setting due to the more severe policies examined such as allowing 35
patients to receive only three prescription items per month.   36
In light of the evidence for adverse consequences, an emerging international trend is to move 37
away from conventional copayment policies. For example, in the United Kingdom 38
prescription charges have been removed in Wales, Scotland and Northern Ireland. 10,11 Recent 39
policy reform in the U.S. has created Value Based Insurance Design (VBID).  VBID provides 40
free or reduced price access to prescription medicines which provide value both at clinical 41
and cost effective levels e.g., medicines used in diabetes or high blood pressure.12 42
Discriminate pricing based on the value of medicines has also been proposed for the 43
European setting.4 44
Considering the risk of copayments to public health, in addition to the risk of elevated 45
healthcare costs due to potential increased use of hospital services, a study of the copayment 46
system in Ireland was imperative. The introduction of the €0.50 copayment in 2010 and its 47
increase to €1.50 in 2013 provided a natural experiment to analyse the policy implication on 48
patient adherence to medicines. 49
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Methods50
51
Ethics 52
Ethical approval for this study was obtained from the Clinical Research Committee of the 53
Cork Teaching Hospitals, Ireland. 54
Study design 55
We used a pre-post longitudinal design with monthly repeated measures. The effects of the 56
€0.50 and €1.50 copayments were analysed separately.  57
Setting 58
The GMS scheme is the national tax-funded health insurance programme in Ireland for low 59
income individuals/families and older people. 13 It provides hospital services and primary 60
health care, including General Practitioner visits and prescription medicines, free at the point 61
of access to approximately 40% of the population.13 The initiation of the copayment system 62
in 2010 ended free access to prescription medicines.  63
 64
The Long Term Illness (LTI) scheme is a second, smaller public insurance scheme, which 65
provides free medications to individuals who have been diagnosed with one of 16 chronic 66
illnesses, for example, epilepsy or diabetes.  Qualification is independent of income. There 67
was no change to the LTI scheme during the course of this study. In their seminal paper that 68
investigated the methods of studies examining drug policies Soumerai et al. recommended 69
the use of before and after measurements along with the use of an appropriate comparison 70
group to minimise fundamental threats to validity.14  The LTI scheme served as a non-71
equivalent comparator group in our analyses for oral diabetes, blood pressure lowering and 72
lipid lowering agents. The remaining medication groups in our study are not typically 73
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covered by the LTI scheme, which precluded it as a comparator for those analyses. Instead, 74
we relied on pre-post comparisons to estimate absolute reductions in adherence on the GMS, 75
a design which still maintains methodological strengths.14 76
Data Source 77
We used national pharmacy claims data held in the Health Service Executive-Primary Care 78
Reimbursement Services (HSE-PCRS) database. These data have been used in 79
pharmacoepidemiological and health policy studies in the past15,16 and have been shown to be 80
accurate.17  Data were at the individual level and included variables for age, gender, drug 81
dispensed classified by World Health Organisation (WHO) Anatomical Therapeutic Class 82
(ATC)  code and the corresponding WHO Daily Defined Dose (DDD), the strength and 83
quantity of medication dispensed and the date of dispensing.   84
Participants and medications 85
According to categories summarised in a Cochrane review18, we designated “essential” or 86
“less-essential” status to eight medication groups to assess whether the impact of the 87
copayments differed depending on type of medication. Medications were identified by WHO-88
ATC code (Supplementary Information 1).  89
We employed a new user design to minimise the risk of prevalent user bias.19  New users 90
were defined as individuals who filled a new prescription for a medication without having 91
had a prescription for that medication, or medication in that group, in the prior six months. 92
Once identified as a new user of a medication, patients could enter the cohort at any time in 93
the six months before copayment introduction/increase. Follow up began on first day of 94
cohort entry and ran until 12 months post policy change for the €0.50 copayment. Follow up 95
was for eight months post the €1.50 copayment due to  incomplete data for 2013 at the time 96
of analysis (Figure 1).Patients were excluded if not continuously eligible on the GMS 97
9
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scheme or if in receipt of weekly phased prescriptions (example flowchart in 98
Supplementary Information 2). Phased prescriptions are monthly prescriptions that are 99
typically dispensed on a week by week basis, for example in cases of complicated 100
polypharmacy with the aim of improving adherence, or in cases of drug misuse.  101
*Insert Figure 1* 102
Study Outcome 103
We evaluated adherence using the Proportion of Days Covered (PDC) method.20 The PDC 104
describes the proportion of days covered by a medication in a given interval and is typically 105
made using two other variables; days’ supply and dispensing date.  In the absence of a days’ 106
supply variable in the HSE-PCRS database,  a days’ supply variable was estimated using the 107
number of WHO DDDs.21 This approach is often used in European pharmacy claims database 108
studies.22,23 109
Using the calculated days’ supply and the first dispensing date, a medication supply diary 110
was made for each patient indicating which days in the study period a patient had medication 111
available to them. From this supply diary, monthly PDCs were measured, running 112
consecutively from cohort entry to the end of follow up for each individual. Due to the new 113
user design, adherence began at 100% for each patient and then, on average, followed the 114
pattern established for new users, namely a gradual reduction to adherence of approximately 115
50%.20 If a dispensing occurred before the previous dispensing ran out, the new dispensing 116
was assumed to begin the day after the end of the prior dispensing and the diary was adjusted 117
accordingly. The PDC was truncated at 1.  If an individual was taking more than one 118
medicine within a medication group, the number of days that a patient had at least one of 119
their medicines available to them was calculated.24 Switching medicines within a medication 120
group was permitted.  121
10

In a sensitivity analysis to test the accuracy of using the number of DDDs to calculate the 122
PDC, we assumed a 30-day supply for each dispensing because an individual is entitled to a 123
maximum of one month supply on the GMS scheme.25 We also tested the performance of 124
quantity of medication dispensed in measuring the PDC.  125
Variables 126
 The pre-post study design is strengthened by its inherent control for time-invariant 127
confounders, such as socio-economic factors.26 We adjusted our models for concurrent 128
medication use inclusive of blood-pressure lowering, lipid lowering and oral-diabetes 129
medicines along with insulin and aspirin. However, these variables did not alter the effect 130
estimates for the intervention, therefore we present age and sex adjusted estimates only.  131
Statistical Methods 132
First, a segmented generalised linear regression model was fitted to estimate changes in PDC 133
immediately after the policy change (change in intercept) and changes in PDC in the months 134
following post policy (change in slope per month).27 Policy effects were included in the 135
model as interaction terms between the GMS group and the policy-specific intercept and 136
slope terms. Then, we accounted for natural trends in adherence by subtracting the change in 137
adherence in the LTI group from the concurrent change in the GMS group. We adjusted for 138
correlations between repeated measures using generalised estimating equations.28 A one 139
month lag period was incorporated to allow the impact of the policy change to take effect, 140
acknowledging that prescriptions are filled every 30 days. For medication groups without a 141
comparator group we assessed the pre-post difference in adherence using a model without the 142
interaction terms.  143
11

We conducted sub-group analyses to assess whether effect modification by age and/or gender 144
may have occurred. Age was categorised as 18-29 years, 30-39 years, 40-49 years, 50-59 145
years, 60-69 years and 70+ years.  146
All data management and analyses were carried out in R studio version 2.15.3.  147
148
Results149
150
The sample sizes for each medication group were quite large (Tables 1 and 2). The LTI 151
population was 5-7 years younger and had approximately 20% less females than the GMS 152
population (Table 1). Diabetes medication usage was higher on the LTI scheme, which was 153
expected. New users of less-essential medications were younger than new users of chronic 154
disease medications in both €0.50 and €1.50 cohorts, except for anti-depressant medications 155
(Table 2). 156
*Insert Tables 1 and 2* 157
After the €0.50 copayment was introduced, adherence in all medication groups fell. 158
Adherence was decreased by -4.8% (95% CI, -5.7 to -4.0) for blood pressure lowering, by -159
3.0% (95% CI, -3.9 to -2.1) for lipid lowering and by -2.4% (95%, -3.5 to -1.3) for oral 160
diabetes medications in GMS patients, relative to the LTI group (Table 3). Absolute 161
reductions in adherence to thyroid hormone were of similar magnitude to other essential 162
medications, but the drop in adherence to anti-depressant medications was much larger (-163
8.3% [95% CI, -8.7 to -7.9]). For two out of the three less-essential medicine groups, PPIs/H2 164
and NSAIDs, the reductions in adherence were bigger than what was observed for most of the 165
essential medicines (Table 3). In contrast, the reduction in adherence to anxiolytics/hypnotics 166
dropped only by -2.0% (95% CI, -2.3 to -1.7).  The change in slope in the post policy period 167
12

indicated a continued reduction in adherence for anti-depressant medications (-0.8% per 168
month, 95% CI,-1.1 to -0.5) and PPIs/H2 (-0.5% per month, 95% CI, -0.9 to -0.3). Using the 169
results for slope changes in the controlled analyses as a guide to interpretation, these 170
reductions may not be significant.  171
*Insert Table 3* 172
The reductions in adherence to blood pressure lowering, lipid lowering and oral diabetes 173
medicines were of smaller magnitude after the increase in copayment from €0.50 to €1.50 174
compared to the introduction of the €0.50 copayment (Figure 2). The same pattern was true 175
for absolute reductions in adherence to thyroid hormone, but adherence to anti-depressant 176
medicines decreased by a larger magnitude after the €1.50 copayment (-10.0%, 95% CI 10.4 177
to -9.6). Adherence to less-essential medications PPIs/H2 and NSAIDs was also reduced by 178
larger amounts after the increase in copayment to €1.50 (Figure 2 and Table 3). In contrast, 179
there was a very small reduction in adherence to anxiolytics/hypnotics (-0.8%, 95% CI -1.0 to 180
-0.5). Changes in slope post policy indicate further reductions in adherence in the months 181
following the increased copayment for thyroid hormone, anti-depressant medications, 182
PPIs/H2 and NSAIDs (Table 3). Using the estimates of slope changes in the analyses with a 183
comparator group to guide interpretation; these slope changes may not be significant. 184
*Insert Figure 2* 185
Sub-group analyses revealed that males had larger reductions than females in adherence to 186
thyroid hormone immediately after each policy (after the 50c policy, -4.3% (95% CI, -5.6 to -187
2.9) vs -1.5% (95% CI, -2.2 to -0.8) respectively and after the €1.50 policy -2.6% (95% CI, -188
3.9 to -1.3) vs -0.17% (95% CI, -0.9 to 0.6) respectively). Additionally, males and those aged 189
>70yrs had larger decreases in adherence to NSAIDs immediately after each policy. Effect 190
modification by age or gender also occurred in the anxiolytics/hypnotics group, the PPI/H2 191
13

group, the lipid lowering medicine group and anti-depressant medication group 192
(Supplementary Information 3).  193
Our sensitivity analyses demonstrated that using number of DDDs to calculate the PDC was 194
the most conservative method, in comparison to using an assumed 30 day supply or quantity 195
dispensed. This was especially true for less-essential medicines, which are often used on an 196
as required basis (Supplementary Information 4).  197
14
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Discussion198
 199
In this pre-post longitudinal study, we found that both €0.50 and €1.50 copayments were 200
associated with larger reductions in adherence to less-essential medicines than essential 201
medicines directly after the policy changes, consistent with previous systematic review 202
findings.18,29 Further decreases in the months following the changes in copayments were very 203
gentle and/or insignificant, which also concurs with the literature.30,31 These results indicate 204
that the impact of the policies was in the period immediately following the policies. In the 205
long term, adherence continued at this new reduced level, as opposed to decreasing even 206
further in the following months.  207
The major exceptions to the observed trends were for anxiolytics/hypnotics and anti-208
depressant medications.  The minimal reductions in adherence to anxiolytics/hypnotics echo 209
findings as far back as the 1970s when Reeder et al. reported little change in the utilisation of 210
sedative/hypnotic mediations after the implementation of a $0.50 copayment in a Medicaid 211
population in the United States.30 In more recent times, Ong et al. in 2003 did not find any 212
reductions in utilisation of anxiolytics and sedatives when a copayment was increased in 213
Sweden, even though it was a much more expensive copayment than examined in our study.32 214
The consistency of these findings over numerous decades points to persistent insensitivity 215
towards copayments for these drugs, likely due to their addictive nature.  216
Our finding that adherence to anti-depressant medications was reduced more than other 217
essential medicines is different to what has been previously reported.  A study by Goldman et 218
al. found that reductions in use of anti-depressant medications were similar to, or less than, 219
reductions in use of other essential medicines when a copayment was doubled.33 In Sweden, 220
an increase in copayment saw a reduction in utilisation of anti-depressant medications for 221
females only. 32 In the Irish setting, there was no effect modification by gender, but the 222
15

decrease we observed was driven by people aged 18- 29 years. There was no change in 223
adherence to anti-depressant medications in Iceland after a €1 increase in 2010.34 The 224
discordance between our results and those reported in the Icelandic study are particularly 225
remarkable given that the policy interventions occurred in similar economic circumstances in 226
2010.  Differences in the demographics of the populations, the types of anti-depressants 227
included and the fact that our study did not have a control group for anti-depressants may 228
explain why our findings differ to previous reports. Further, our results may have been 229
vulnerable to confounding by the underlying economic recession during the study period. In 230
this period, diagnoses of depression increased, as did suicides.35,36 231
Is the small copayment, such as those studied in this paper, a useful policy tool?   A key 232
consideration is that the effect on essential medicines was generally smaller than for less-233
essential ones. But within these two categories there are exceptions, and care is needed to 234
avoid the consequences of reduced use of, for example, antidepressants. We also need a 235
better understanding of the clinical consequences of reductions in use of essential medicines, 236
even if these reductions are small – for instance, how important was the ~4% reduction in use 237
of blood pressure lowering drugs with regard to outcomes such as heart attack or stroke. 238
Conversely, the reductions observed for the less-essential medicines may be thought desirable 239
given that some of these drugs have been found to be inappropriately prescribed in Ireland.240
16,39
  However, if a reduction in the use of inappropriately used medicines was a key goal, 241
then other measures may be required when the results for anxiolyics/hypnotics are 242
considered.  243
Our findings are in line The Rand Health Insurance Experiment (HIE), which is to date the 244
strongest study in the area of cost-sharing. The HIE found that after randomising families to 245
different levels of cost-sharing, there was little difference between the groups for medications 246
used in chronic disease but the use of less-essential medicines decreased for people who paid 247
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more for them.37 Our results also echo observational studies dating as far back as the 1970s 248
that examined similar small copayments to the ones we studied.38,39  Given the amount of 249
time that has passed with natural changes in currency, the actual price paid in our study 250
represents a smaller proportion of income. This suggests the practice of paying a small 251
amount may be sufficient to thwart moral hazard rather than the price, a feature which is 252
supportive of a small copayment.  253
However, caution must be exercised in advocating for a small copayment given the 254
limitations of our study. We did not have a comparator population for each of the medication 255
groups in our study. Despite this, our use of the LTI group, while a non-equivalent 256
comparator, was most useful for studying adherence in three chronic disease medications, 257
reflecting any extraneous influences on adherence e.g. changes in national chronic disease 258
health policies.40 Pharmacy claims data do not indicate consumption of medications, just 259
dispensing. Our categorisation of medication groups as essential or less-essential does not 260
take into account instances where less-essential medicines may be a required therapy e.g., 261
PPIs in peptic ulcer disease. Related to this, we measured adherence to less-essential 262
medicines using the same method for essential medicines. Less-essential medicines, 263
especially NSAIDs, may be used on “as required” basis to which our method may be 264
somewhat insensitive. However, it is difficult to measure adherence to medicines that are 265
used sporadically, thus we used the method that is most frequently cited in the literature for 266
claims data. . We have not assessed clinical outcomes, rather we used adherence as a 267
surrogate outcome.41  268
Our study was strengthened by using a population level database, thus we had full dispensing 269
information for the entire GMS population. Although the GMS population is by definition 270
comprised of low-income people, some socio-economic variation may still persist within the 271
population. While we carried out subgroup analyses according to age and gender, we did not 272
17

have access to socio-economic data, which calls for further research.   Our data were at the 273
individual level, thus avoiding ecological fallacy.14 We employed the most appropriate study 274
design and statistical techniques to study drug policy interventions.14,27  275
 276
Conclusion 277
 278
Our results show that small copayments for prescription medicines in Ireland are associated 279
with larger decreases in the use of less-essential medicines than essential ones.  The 280
exception was medicines used in depression, a result which requires further investigation and 281
caution. 282
 283
The extent to which small copayments can reduce moral hazard and increase revenue without 284
significant harm to patients may depend on copayment policies being combined with other 285
policy interventions. First, supply side measures should continue to be implemented, 286
controlling the cost of medicines to the government, and thus reducing the burden of patient 287
cost-sharing. Secondly, awareness and understanding of the role of essential medicines 288
should be emphasised by healthcare professionals, promoting rational choices amongst 289
patients.  290
Importantly, the effects of a €2.50 copayment (introduced December 2013) in this Irish 291
publicly insured population have yet to be assessed. This, along with careful monitoring of 292
vulnerable groups and accessing data on clinical outcomes is crucial to the future 293
development of this copayment policy. Until such research is completed, further increases to 294
the price would not be a prudent way forward given that copayments have been associated 295
with negative patient outcomes in the past. 296
18
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Table 1 Baseline characteristics of new users of essential medicines for the €0.50 copayment and the €1.50 copayment 
 
 
€0.50     €1.50 
 GMS LTI  GMS LTI 
Blood pressure lowering medicines n=39,314 n= 3,831  n= 37,007 n=3,112 
Mean Age –yrs (SD) 62.1 (±16.4) 56.3 (±19.7)  60.4 (±16.7) 57.7 (±21.3) 
Female – n (%) 21,935 (55.8) 1,210 (31.6)  20,200 (54.6) 985 (31.7) 
Medication use at baseline – n (%)      
Aspirin  4,089 (10.4) 371 (9.7)  3,590 (9.7) 281 (9.0) 
Lipid lowering medicines 5,268 (13.4) 433 (11.3)  5,440 (14.7) 401 (12.9) 
Oral diabetes medicines  1,054 (2.7) 552 (14.4)  1,073 (2.9) 557 (17.9) 
Insulin 236 (0.6) 277 (7.2)  296 (0.8) 229 (7.4) 
      
      
Lipid lowering medicines n= 33,394 n=4,217  n=29,619 n=3,351 
Mean Age –yrs (SD) 63.6 (±13.6) 56 (±18.9)  63.2 (±13.4) 57 (±10.7) 
Female – no. (%) 17,942 (53.7) 1,327 (31.5)  15,300 (51.7) 1,095 (32.7) 
Medication use at baseline – n (%)      
Aspirin  5,076 (15.2) 523 (12.4)  4,206 (14.2) 385 (11.5) 
Blood pressure lowering medicines 9,117 (27.3) 671 (15.9)  8,323 (28.1) 570 (17) 
Oral diabetes medicine  1,536 (4.6) 856 (20.3)  1,540 (5.2) 781 (23.6) 
Insulin 367 (1.1) 338 (8.0)  373 (1.3) 301 (9.0) 
      
      
Oral diabetes medicines n= 7,145 n= 4,076  n= 7,007 n=3,011 
Mean Age –yrs (SD) 62.8(±15) 55.4 (±11.4)  61.4(±15.8) 56.1 (±22) 
Female – n (%) 3,395 (47.5) 1,306 (32.0)  3,253 (46.4) 1,028 (34.1) 
Medication use at baseline – n (%)      
Aspirin  1,710 (23.9) 392(6.2)  1,638 (23.4) 251 (8.3) 
Lipid lowering medicines 2,213 (31) 437(10.7)  2,181 (31.1) 394 (13.1) 
Blood pressure lowering medicines 2,799 (39.2) 459 (11.3)  2,775(39.6) 372 (12.4) 
Insulin 229 (3.2) 206 (5.2)  300 (4.3) 200 (6.6) 
      
      
Thyroid hormone n= 7,654 -  n=8,104 - 
Mean Age –yrs  (SD) 58.9 (±17.6) -  57.3 (±18.1) - 
Female – n (%) 5,946 (77.7) -  6,095 (75.2) - 
Medication use at baseline – n (%)      
Aspirin  267 (3.5) -  1,049 (12.9) - 
Lipid lowering medicines 1,357 (17.7) -  1,592(19.6) - 
Blood pressure lowering medicines 1,638 (21.4) -  1,869(23.1) - 
Oral diabetes medicines 267(3.5) -  343(4.2) - 
Insulin 95(1.2) -  106(1.3) - 
      
      
Anti-depressant medicines n=39,432 -  n=45,220 - 
Mean Age –yrs  (SD) 52.8 (±19.8) -  50.2 (±19.7) - 
Female – n (%) 25,945 (65.8) -  28,842 (63.8) - 
Medication use at baseline – n (%)      
Aspirin  6291 (16.0) -  6,144 (13.6) - 
Lipid lowering medicines 7,715 (19.6) -  8,598 (13.6) - 
Blood pressure lowering medicines 9,816 (24.9) -  10,707 (23.7) - 
Oral diabetes medicines 1,574 (4.0) -  1,878 (4.2) - 
Insulin 433 (1.1) -  523 (1.2) - 
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Values missing for thyroid hormone and anti-depressant medicines in the LTI column because these drugs are 
typically not covered on the LTI scheme 
 
NSAIDs : Non-steroidal anti-inflammatory drugs 
PPIs/H2: Proton Pump Inhibitors/H2 antagonists 






Table 2 Baseline characteristics of new users of less-essential medicines for the €0.50 copayment and the €1.50 copayment  
 €0.50  €1.50 
  
GMS 
  
GMS 
PPIs/H2 receptor antagonists n=74,986  n=88,917 
Mean Age –yrs  (SD) 56.2 (±19.1)  52.8 (±19.6) 
Female – n (%) 43,979 (58.6)  51,836 (58.3) 
Medication use at baseline – n (%)    
Aspirin  14,289 (17.8)  13,027 (14.7) 
Lipid lowering medicines 17,602 (21.9)  18,562 (20.9) 
Blood pressure lowering medicines 22,874(28.5)  23,181 (26.1) 
Oral diabetes medicines 3,510 (4.4)  3,952 (2.6) 
       Insulin 829 (1.0)  912 (1.0) 
    
 
   
NSAIDs n=136,111  n=132,589 
Mean Age -yrs (SD) 53 (±19.5)  50.5 (±19) 
Female –n (%) 82,565 (60.7)  79,747 (60.1) 
Medication use at baseline –no. (%)    
Aspirin  26,152 (19.2)  21,117 (15.9) 
Lipid lowering medicines 33,208 (24.4)  30,110 (22.7) 
Blood pressure lowering medicines 41,320 (30.4)  35,902 (27.1) 
Oral diabetes medicines 6,690 (4.9)  6,494 (4.9) 
       Insulin 1,554 (1.1)  1,484 (1.1) 
    
    
Anxiolytics/Hypnotics n=64,462  n=73,665 
Mean Age -yrs (SD) 55 (±19.1)  53yrs (±19.1) 
Female –n (%) 40,824 (63.3)  45,975 (62.4) 
Medication use at baseline –n (%)    
Aspirin  11,700 (18.2)  12,037 (16.3) 
Lipid lowering medicines 14,845 (23.0)  17,294 (23.5) 
Blood pressure lowering medicines 18,729 (29.1)  21,049 (28.6) 
Oral diabetes medicines 2,775 (4.3)  3,465 (4.7) 
       Insulin 685 (1.1)  853 (1.2) 
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NSAIDs : Non-steroidal anti-inflammatory drugs 
PPIs/H2: Proton Pump Inhibitors/H2 antagonists 
Values missing for thyroid hormone, anti-depressant medications and all less-essential medicines because these drugs are typically not covered on the LTI scheme. 
Table 3 Impact of €0.50 copayment introduction on adherence
 Short term % change in adherence  
(95% CI) 
 Long term % change in adherence (per month) 
(95% CI) 
 
GMS LTI DIFF  GMS LTI DIFF 
Essential medicines        
Blood pressure lowering medicines -5.0 (-6.8 to -3.4) -0.2 (-1.1 to 0.6) -4.8 (-5.7 to -4.0)  -0.5 (-0.9 to -0.1) -0.9 (-1.2 to -0.7) 0.5 (0.3 to 0.6) 
Lipid lowering medicines -4.7 (-6.5 to -2.9) -1.7 (-2.6 to -0.8) -3.0 (-3.9 to -2.1)  -1.2 (-1.5 to -0.7) -1.1 (-1.3 to -0.8) -0.1 (-0.2 to 0.1) 
Oral diabetes medicines -4.0 (-6.0 to -1.9) -1.6 (-2.5 to -0.6) -2.4 (-3.5 to -1.3)  -0.5 (-0.9 to 0.2) -0.9 (-1.3 to -0.5) 0.4 (0.3 to 0.8) 
Thyroid hormone -2.1(-2.8 to -1.5) - -  -0.4 (-0.8 to -0.1) - - 
Anti-depressant medicines -8.3( -8.7 to -7.9) - -  -0.8 (-1.1 to -0.5) - - 
 
       
Less-essential medicines        
PPIs/H2 antagonists -9.5 (-9.8 to -9.1) - -  -0.5 (-0.9 to -0.3) - - 
NSAIDs -5.7 ( -5.9 to - 5.5) - -  0.4 (0.1 to 0.7) - - 
Anxiolytics/Hypnotics -2.0 (-2.3 to -1.7) - -  -0.2 (-0.5 to 0.01) - - 
        
Impact of €1.50 copayment introduction on adherence 
Essential medicines        
Blood pressure lowering medicines -5.3 (-7.1 to -3.5) -0.9 (-1.8 to 0.01) -4.4 (-5.3 to -3.5)  -1.2 (-1.6 to -0.6) -1.4 (-1.7 to -1.0) 0.2 (0.04 to 0.4) 
Lipid lowering medicines -4.7 (-6.8 to -2.6) -3.5 (-4.5 to -2.5) -1.2 (-2.3 to -0.1)  -1.6 (-2.1 to -1.0) -1.7 (-2.0 to -1.3) 0.1 (-0.1 to 0.3) 
Oral diabetes medicines -4.9(-7.2 to -2.7) -5.2 (-6.3 to -4.2) 0.3 (-0.9 to 1.5)  -1.8 (-2.3 to -1.6) -1.9 (-2.1 to -1.7) 0.1 (-0.2 to 0.1) 
Thyroid hormone -0.7 (-1.4 to -0.1) - -  -1.0 (-1.3 to -0.5) - - 
Anti-depressant medicines -10.0 (-10.4 to -9.6) - -  -1.5 (-1.8 to -1.2) - - 
 
       
Less-essential medicines        
PPIs/H2 antagonists -13.5 (-13.9 to -13.2) - -  -1.2 (-1.5 to -0.9) - - 
NSAIDs -8.9 (-9.2 to -8.7) - -  -1.4 (-1.6 to -1.1) - - 
Anxiolytics/Hypnotics -0.8 (-1.0 to -0.5) - -  -0.2 (-0.6 to 0.1) - - 
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Figure 1: Demonstration of new user identification, cohort entry and follow up for 50c and 
€1.50 policy interventions 
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Figure 2: Results for the short term effects of 50c and €1.50 copayment policies plotted for 
each medication group. 
 Results plotted for blood pressure lowering,lipid lowering and oral diabetes medications are relative 
differences. Results plotted for remaining medication groups are absolute differences in adherence observed in 
the GMS group.  
NSAIDs – Non-steroidal anti-inflammatory drugs.  
PPIs/H2 – Proton Pump Inhibitors/H2 antagonists 
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